GlassScriptPhysician profile
Tapas J Ghose
NPI 1326089285
$9,289.03
in general payments reported to CMS, 2019-2025
19 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,764 · 2020: $767 · 2021: $44.01 · 2022: $2,167 · 2023: $333 · 2024: $1,314 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Travel and Lodging: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.91 |
| Travel and Lodging | $1,751.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,776.62 | 2019-2025 | Perclose Proglide, Supera, Esprit |
| Philips North America LLC | $2,609.91 | 2019-2022 | |
| Boston Scientific Corporation | $1,808.56 | 2019-2025 | Ekosonic, General - Balloons, General - Vascular Access |
| Shockwave Medical, INC | $150.18 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $143.66 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $141.84 | 2023-2024 | Corevalve Evolut R, Venaseal, Resolute Onyx |
| E.R. Squibb & Sons, L.L.C. | $99.54 | 2019-2023 | Camzyos, Eliquis |
| Chiesi USA, INC. | $99.05 | 2021-2022 | |
| Penumbra, INC. | $94.05 | 2025 | Indigo System |
| Asahi Intecc USA, INC. | $70.69 | 2025 | Asahi Peripheral Vascular Wires |
| Pfizer INC. | $62.47 | 2020-2025 | |
| Amgen INC. | $57.26 | 2019-2025 | Repatha, Repatha |
| Irhythm Technologies, INC. | $45.06 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $37.04 | 2024 | |
| Novo Nordisk INC | $24.54 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.82 | 2019 | |
| Medtronic Vascular, INC. | $16.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tapas Ghose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.